Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-arterial liposomal doxorubicin for recurrent glioblastoma (Phase II)
2008-002454-37Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in glioblastoma (GBM), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoints: Progression-free survival at 6 months (PFS% at 6 months) and Survival. Started Nov 2008; status: completed.
02
Drugs
doxorubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-002454-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002454-37.